Loading...
Docoh

Phio Pharmaceuticals (PHIO)

News

From Benzinga Pro
Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells
16 May 22
Biotech, News, Penny Stocks, Health Care, General
12 Health Care Stocks Moving In Monday's Pre-Market Session
16 May 22
Pre-Market Outlook, Markets, Movers
Phio Pharmaceuticals Presents New Data Demonstrating PH-894 Enhances Activity Of HER2-CAR-T Cells At ASGCT 2022
16 May 22
Biotech, News, Events, General
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today
Phio Pharmaceuticals Q1 EPS $(0.19) Up From $(0.32) YoY
12 May 22
Earnings, News
Phio Pharmaceuticals (NASDAQ:PHIO) reported quarterly losses of $(0.19) per share. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year.
Phio Pharmaceuticals Announces Upcoming Presentation Of PH-894 Data At ASGCT 25th Annual Meeting 2022
2 May 22
Biotech, News, Events, General
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,
Phio Pharmaceuticals Open enrollment in Phase 1b Trial of PH-762 for the Treatment of Advanced Melanoma
26 Apr 22
Biotech, News, Penny Stocks, Health Care, FDA, General
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has started enrolling patients in the Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.
Phio Pharma Reports Commencement Of Its Phase 1b Trial Of PH-762 For Treatment Of Advanced Melanoma
26 Apr 22
Biotech, News, FDA, General
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform,
22 Stocks Moving in Friday's Pre-Market Session
22 Apr 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Moving iMage Technologies, Inc. (NASDAQ: MITQ) rose 41.7% to $1.63 in pre-market trading. Moving iMage Technologies and SNDBX reported a strategic partnership for gaming and e-Sports.
Phio Pharmaceuticals To Present At Tumor Immune Microenvironment Workshop Of The Society For Immunotherapy Of Cancer On Apr. 21
18 Apr 22
Biotech, News, Events, General
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Apr 22
Movers
Gainers
12 Health Care Stocks Moving In Monday's Pre-Market Session
11 Apr 22
Movers
Gainers Hoth Therapeutics (NASDAQ:HOTH) stock rose 156.5% to $1.58 during Monday's pre-market session. The market value of their outstanding shares is at $37.8 million.
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
10 Apr 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, Top Stories, General
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Phio Pharma Shares Shine After Positive PH-894 Preclinical Data At AACR Presentation
8 Apr 22
Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General
Phio Pharmaceuticals Corp (NASDAQ: PHIO) has
12 Health Care Stocks Moving In Friday's Intraday Session
8 Apr 22
Intraday Update, Markets, Movers
Phio Pharmaceuticals Presents Positive Data On PH-894 Demonstrating Antitumor Efficacy In Model Of PD-1 Refractory Disease At AACR Annual Meeting 2022
8 Apr 22
News, FDA, Events
hio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today
Phio Pharmaceuticals Granted U.S. Patent #11,279,934 Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
22 Mar 22
Options, Markets
View patent here
Phio Pharmaceuticals Announces Upcoming Presentation Of PH-894 Data At The AACR Annual Meeting 2022
8 Mar 22
News, FDA, Events
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today
12 Health Care Stocks Moving In Thursday's After-Market Session
3 Mar 22
Movers
Gainers Puma Biotechnology (NASDAQ:PBYI) shares moved upwards by 12.0% to $2.61 during Thursday's after-market session. The company's market cap stands at $106.7 million. As per the press release, Q4 earnings came out today.
Phio Pharmaceuticals Initiates In Vivo Studies Of INTASYL Based Antivirals Against SARS-CoV-2
22 Feb 22
News, FDA
Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today

Press releases

From Benzinga Pro
Phio Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
12 May 22
Earnings, Press Releases
First-in-human clinical study of PH-762 for the treatment of advanced melanoma open for enrollment Expect to finalize IND-enabling studies for PH-894 in the second half of 2022 MARLBOROUGH, Mass., May 12, 2022
Phio Pharmaceuticals Announces Senior Leadership Personnel Change
5 May 22
Press Releases
MARLBOROUGH, Mass., May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022
3 May 22
Press Releases
MARLBOROUGH, Mass., May 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022
2 May 22
Press Releases
Marlborough, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors
2 May 22
Press Releases
MARLBOROUGH, Mass., May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma
26 Apr 22
Press Releases
MARLBOROUGH, Mass., April 26, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Thinking about buying stock in Indonesia Energy, Phio Pharmaceuticals, Redbox Entertainment, DiDi Global, or Cleveland-Cliffs?
22 Apr 22
Opinion, Press Releases
NEW YORK, April 22, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDO, PHIO, RDBX, DIDI, and CLF.
Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer
18 Apr 22
Press Releases
MARLBOROUGH, Mass., April 18, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Thinking about buying stock in Agile Therapeutics, Polarityte, Bed Bath & Beyond, Tellurian, or Phio Pharmaceuticals?
13 Apr 22
Opinion, Press Releases
NEW YORK, April 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, PTE, BBBY, TELL, and PHIO.
Thinking about buying stock in Nio, Genocea Biosciences, Phio Pharmaceuticals, IQIYI, or Aterian?
11 Apr 22
Opinion, Press Releases
NEW YORK, April 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, GNCA, PHIO, IQ, and ATER.
Healthcare Breakthroughs: Veru, Nova Mentis, Phio, and PharmaDrug; Visionary CEOs Report Latest Advances in New Drug Development for COVID-19, Cancers, Glaucoma, and Autism
11 Apr 22
Health Care, Markets, Press Releases
NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO's of: Nova Mentis Life Sciences
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022
8 Apr 22
Press Releases
MARLBOROUGH, Mass., April 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update
22 Mar 22
Earnings, Press Releases
Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. MARLBOROUGH, Mass., March 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022
8 Mar 22
Press Releases
MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering
Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2
22 Feb 22
Press Releases
MARLBOROUGH, Mass., Feb. 22, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering